Should I buy McKesson Corporation (MCK) stock or is it too late?

McKesson Corporation · Health Care · price $962
Logo McKesson CorporationSee the full McKesson Corporation (MCK) profile
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Citigroup — 67% of its targets hit on this sector (516 calls tested). It aims for $1,000 (+4.0 %), call made on July 25, 2026, maturing on July 25, 2027 (81 d ago).

The 7 reliable analysts $1,000+4.0 %
The 2 other firms $930-3.3 %
How to read it: the 7 reliable firms are not filtered by optimism — 6 aim above the price, 1 below, hence their $1,000 median. “The 2 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on McKesson Corporation

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.
Firm% rightGain vs sectorCallsAims for
Citigroup91 %+30.7 %11$1,000 +4%
TD Cowen100 %+30.3 %5$1,006 +5%
UBS100 %+29.9 %12$1,080 +12%
Morgan Stanley97 %+29.2 %30$916 -5%
Baird92 %+24.6 %12$927 -4%
Evercore ISI Group88 %+21.3 %8$1,000 +4%
Deutsche Bank73 %+17.5 %11$856 -11%
JP Morgan64 %+15.5 %11$1,015 +6%
In short — Should you invest in McKesson Corporation? Is it too late, still worth it? Analysts are overwhelmingly positive (80% buy, median target $1,000, i.e. +4%), and the most reliable on MCK targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

  • 80% of analysts rate it a buy (Buy consensus, 10 ratings) — a sign of market conviction.
  • The most reliable firm on MCK, Leerink Partners (100% hit rate, 4 scored calls), targets $1,070 (call made on October 7, 2026, maturing on October 7, 2027) (+11%) in its most recent call.

⚠️ Reasons to hesitate

  • The consensus is not unanimous: of 10 ratings, 2 are neutral.
  • Limited upside: the median target is only +4% from the current price.
  • A 12-month target is not a guaranteed path: the price can fall in the meantime.
  • Negligible dividend (0.4% yield): your return depends mostly on price appreciation.

The analyst consensus on MCK

Median target $1,000 (+4%) · 10 ratings · Buy consensus

Strong Buy00%
Buy880%
Hold220%
Sell00%
Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in McKesson Corporation now?

We won't decide for you. The facts: 80% of analysts rate it a buy, median target $1,000 (+4%), and Leerink Partners (most reliable on MCK, 100%) targets $1,070. Weigh that against valuation (P/E ~26). This is not personalized advice.

Is it too late to invest in McKesson Corporation?

Not according to analysts: the median target ($1,000) is still +4% above the current price ($962) (most reliable on MCK: Leerink Partners, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is McKesson Corporation still worth investing in?

It depends on the gap between the price ($962) and its estimated value: analysts target $1,000 on median (+4%), with 80% buys (most reliable on MCK: Leerink Partners, 100%). Cross-check with their real reliability on MCK and the cautions above. Information, not advice.

What's the main risk in buying MCK?

The consensus is not unanimous: of 10 ratings, 2 are neutral.

→ Go deeper: the full McKesson Corporation profile (consensus, analyst reliability, price target, performance).

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)